The healthcare and pharmaceutical sector saw significant regulatory and commercial activity today. Federal Medicaid work requirements are projected to lower insurance coverage by millions while saving hundreds of billions over the next decade, and several major drugmakers face price-fixing settlements and state lawsuits over insulin costs. Concurrently, major licensing and supply deals involving Novo Nordisk, Eli Lilly, WuXi Biologics, and Boryung expanded commercial pipelines and manufacturing footprints globally.
01Policy
GOP States Set Strict Work Rules as New Medicaid Regulations Take Effect
New federal work requirements taking effect in January will result in 7.5 million fewer people having health insurance and save the federal government $887 billion over the next decade, according to Congressional Budget Office estimates cited by Fortune. The mandate applies to up to 20 million lower-income adults without children who are enrolled in Medicaid through an optional expansion across 40 states and the District of Columbia. Beneficiaries must work or volunteer at least 80 hours each month or maintain half-time student status to qualify for coverage. While federal rules allow states to accept a recipient's word for medical exemptions during the first year, at least six states are barring self-attestation immediately. Arkansas, Idaho, Indiana, New Hampshire, North Carolina and Ohio require formal documentary evidence of medical frailty starting next year. Democrats in 25 states are currently suing over the harsher rules, arguing that requiring physician documentation creates an insurmountable barrier for applicants who cannot afford a doctor visit. Supporters of the stricter approach argue that self-attestation encourages fraud and inflates program costs. States will be permitted to accept self-attestation just once per enrollment period beginning in 2028, after which documentation must be provided every 12 months.
Generic Drug Manufacturers Settle Antitrust Claims for $96 Million
Six manufacturers agreed to pay more than $96 million to settle claims after a coalition of 48 attorneys general accused them of secretly fixing prices on more than 100 generic medications. The litigation centers on purchases made between May 1, 2009, and December 31, 2019, covering everyday drugs ranging from antibiotics to heart medications. Executives allegedly coordinated price increases through phone calls, emails, and meetings, with some increases topping 1,000 percent. The settlement includes $29 million from Glenmark Pharmaceuticals, which allocates roughly $20.7 million for consumers and about $8.9 million for administration and litigation costs. Claimants have until March 8, 2027, to file for compensation.
Novo Nordisk Inks Up to $1.3B Deal With Nanexa for Obesity Injectables
Novo Nordisk struck a 1.165 billion euro, or $1.33 billion, licensing agreement with Nanexa to access the Swedish biotech's long-acting drug delivery technology for obesity and Type 2 diabetes treatments. The deal grants Novo an exclusive global license to apply Nanexa's PharmaShell platform to up to five programs targeting cardiometabolic diseases. PharmaShell uses an inorganic coating on drug particles to form slow-dissolving injection site depots, which Novo intends to use to extend dosing windows to monthly and quarterly frequencies. The financial terms include 615 million euros, equivalent to $700 million, in upfront payments and development and regulatory milestones, alongside 550 million euros, or $626 million, tied to sales milestones. Neither company disclosed the specific size of the upfront cash payment. The pact follows recent disclosures from Novo's chief scientific officer Martin Holst Lange regarding plans to initiate human dosing for a once-monthly candidate over the next year.
WuXi cleared a two-week unannounced good manufacturing practice inspection at its Wuxi Mashan manufacturing site. The routine audit covered multiple approved products including monoclonal antibodies, bispecific antibodies, fusion proteins, and enzyme products to reinforce commercial supply reliability for the U.S. market. Over the past 13 years, the site achieved a 100 percent success rate across more than 600 regulatory and client audits while supporting the global launch of over 20 biologics. As of the end of June 2026, the company successfully passed 49 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 166 facility licence approvals. The company also passed more than 2,000 GMP quality audits by global clients, including over 280 audits by EU Qualified Persons. Currently, the company operates 26 drug substance facilities and 19 drug product facilities within its global network, supporting 1,064 integrated client projects as of June 30, 2026. These projects include 78 in and 28 in commercial manufacturing.
Eli Lilly Partners With InnoCare in Licensing Deal Worth Up to $3.35 Billion
Eli Lilly has agreed to pay up to $3.35 billion to partner with Beijing-based InnoCare Pharma on five drug discovery targets. Lilly is committing $100 million in upfront and near-term payments to fund the research, backed by another $3.25 billion in development and commercial milestones. InnoCare will also receive single-digit tiered royalties on annual net sales for any products that reach the market. The collaboration will deploy InnoCare's proprietary drug discovery platform against up to five targets spanning cancer and autoimmune diseases, though the partners have not disclosed specific indications. The alliance represents the latest cross-border licensing pact for InnoCare, following prior agreements with Biogen and Zenas BioSciences. For Lilly, the deal adds to a 2026 and licensing spending spree estimated above $32 billion, driven by surging sales of its weight-loss and diabetes treatments.
Boryung Signs $277 Million Anticancer Drug Supply Deal in China
Boryung has signed a seven-year agreement worth $277.14 million to supply the cancer drug Taxotere to Yifan Pharmaceutical in China. The contract marks the largest supply deal in the South Korean drugmaker's history. The agreement includes minimum annual purchase commitments and compensation provisions for shortfalls, providing multi-year visibility. Boryung will initially supply the drug through existing manufacturing arrangements before transferring production to its Yesan Campus in Korea, a transition that requires technology transfers and regulatory approvals. China represents the largest market by sales among the countries covered by Boryung's of Taxotere's global business from Sanofi. Yifan Pharmaceutical manufactures and markets drugs in China, including sales of the Roche-originated cancer drug Xeloda. Boryung Chief Strategy Officer Kim Sung-jin stated that the long-term demand base demonstrates the translation of its global essential medicines business into actual revenue. Boryung aims to surpass 300 billion won in global sales by 2030 through brand acquisitions, manufacturing internalization, and expanded contract manufacturing operations.
State of Florida Files Antitrust Lawsuit Against Eli Lilly, Sanofi, and CVS
The State of Florida filed an lawsuit against Eli Lilly, Novo Nordisk, and Sanofi on September 22, 2026, alleging that the major drug manufacturers colluded with pharmacy benefit managers to inflate diabetes medication prices. The complaint, lodged in Florida's 11th Judicial Circuit in Miami-Dade County by Attorney General James Uthmeier, also names CVS Caremark, Express Scripts, and OptumRx, alongside rebate aggregators Zinc, Ascent, and Emisar, and UnitedHealthcare Insurance. The defendant manufacturers supply more than 90% of the world's insulin, while the targeted pharmacy benefit managers process about 80% of U.S. prescriptions. According to the state's filing, drugmakers deliberately drove up published list prices for insulin and medications like Ozempic, Trulicity, Victoza, and Soliqua, subsequently returning substantial rebates to the benefit managers to secure preferred formulary placement. Uthmeier cited previous executive testimony revealing that Eli Lilly returns roughly $210, or about 75%, of a $280 vial of Humalog to benefit managers and aggregators. Uninsured patients, those meeting deductibles, and consumers on percentage-based coinsurance absorb these elevated sticker prices rather than the negotiated net prices, leaving approximately 2.3 million Florida adults with diabetes vulnerable to heavy financial strain. The lawsuit brings two counts under the Florida Deceptive and Unfair Trade Practices Act and one count under the Florida Antitrust Act, seeking permanent injunctions, civil penalties, and damages.
Large licensing deals and cleared inspections strengthen drug development pipelines, yet legal liability from price-fixing claims and changing Medicaid rolls threaten broader commercial revenue. Whether expanding oncology and metabolic portfolios can offset looming state litigation and shifting coverage norms remains uncertain.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.